RecruitingPhase 1NCT07545811

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants With Prostate Cancer

Sponsor

Janux Therapeutics

Enrollment

43 participants

Start Date

Apr 15, 2026

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer Metastatic Castration-resistant Prostate Cancer Castration-resistant Prostate Cancer

Summary

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called JANX014 for people with castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALJANX014

JANX014 will be administered via IV dosing

Locations(1)

Research Site

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07545811

Related Trials

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT056166501 location

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT0548921196 locations

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803330 locations

Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

NCT009691116 locations

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779240 locations